Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

CJC-1295 Explained

CJC-1295 is an experimental long-acting GHRH analogue studied for its effects on growth hormone and IGF-1 in healthy adults.

Why we wrote this. CJC-1295 is often described through marketing claims. This primer separates measured hormone effects from unproven clinical benefits.

In this article (5 sections)
  1. What CJC-1295 is
  2. How the hormone signal changes
  3. What the human evidence shows
  4. Approval status and evidence limits
  5. What we do not know yet

CJC-1295 is an experimental, long-acting analogue of growth hormone-releasing hormone, usually shortened to GHRH. GHRH is a signal from the hypothalamus that tells the pituitary gland to release growth hormone. Small studies in healthy adults found that CJC-1295 increased growth hormone and insulin-like growth factor 1, or IGF-1, for days after an injection[1]. That finding shows a hormonal effect. It does not establish that CJC-1295 treats an illness, improves recovery or is safe for long-term unsupervised use.

The published human work is early phase and focused mainly on pharmacology, meaning what the compound does in the body and how long its effects last. It did not provide confirmatory evidence for an approved indication. Readers should therefore treat CJC-1295 as an investigational compound, not as an established alternative to an approved medicine. Our CJC-1295 research page separates those measured hormone changes from the broader claims found in product marketing.

What CJC-1295 is

CJC-1295 was designed to last longer than natural GHRH. In a randomized, placebo-controlled study, researchers described it as a long-acting GHRH analogue and tested single and repeated subcutaneous administrations in healthy adults aged 21 to 61[1]. Subcutaneous means delivered into the tissue beneath the skin. This was a research procedure, not a dosing recommendation.

The molecule's long action was linked to a drug-affinity complex that binds to circulating albumin, a common blood protein. The study estimated a half-life of 5.8 to 8.1 days[1]. Half-life is the time needed for the measured amount of a compound to fall by half. A long half-life can extend biological effects, but it can also make an unwanted effect slower to reverse.

How the hormone signal changes

The first trial found dose-related increases in average growth hormone concentrations for at least six days and increases in average IGF-1 concentrations for roughly nine to eleven days after a single administration[1]. With repeated administrations, average IGF-1 stayed above baseline for up to 28 days. These laboratory outcomes show target engagement, which means the compound affected the pathway it was designed to affect. They are not proof of a patient benefit.

A separate study examined overnight growth hormone secretion before and one week after one research administration in healthy men. Growth hormone secretion increased while its pulse pattern was preserved. Basal, or trough, growth hormone rose markedly, while the frequency and size of the pulses did not change[2]. This is why CJC-1295 is often described as extending GHRH signalling rather than replacing growth hormone directly.

That mechanism does not identify a proven therapeutic use. Growth hormone and IGF-1 affect many tissues, so a change in their blood concentrations cannot be translated automatically into claims about muscle, fat loss, sleep, injury healing or ageing. Each clinical claim would need its own controlled trial with relevant outcomes and adequate follow-up.

What the human evidence shows

The principal published trial consisted of two randomized, double-blind, placebo-controlled, ascending-dose studies lasting 28 and 49 days[1]. The abstract reports no serious adverse reactions and describes the compound as relatively well tolerated in that short research setting. Short-term tolerability in selected healthy volunteers cannot establish long-term safety, safety in people with medical conditions or safety of products bought outside a regulated trial.

The studies also do not validate the identity, concentration or sterility of any commercial vial using the CJC-1295 name. A scientific paper evaluates a defined investigational material under a protocol. It does not authenticate products sold through unrelated websites, clinics or social-media channels.

Approval status and evidence limits

The cited studies discuss potential future clinical utility, but potential is not approval. They do not contain a medicine label, approved indication or regulator-authorized dosing schedule. Claims that CJC-1295 is approved for recovery, bodybuilding, anti-ageing or general wellness would go beyond this evidence.

Country rules can differ, and classification may depend on how a product is presented or supplied. Readers in Denmark can start with our Denmark regulation overview. An absence from an official price list is not permission to import or use a product. Regulatory and medical questions should be checked with the relevant authority and a qualified healthcare professional.

What we do not know yet

We do not have large, long-duration trials showing that CJC-1295 improves a clinical outcome. The published studies do not resolve long-term cardiovascular, metabolic or cancer-related safety questions, nor do they establish safety in adolescents, pregnancy, older adults or people with pituitary disease. They also do not provide evidence for combining CJC-1295 with other growth hormone secretagogues.

The clean conclusion is narrow: CJC-1295 produced sustained changes in growth hormone and IGF-1 in small, controlled studies of healthy adults. Everything beyond that requires separate evidence. Anyone considering a product sold under this name should discuss the uncertainty with a qualified clinician rather than treating hormone changes as a guaranteed health benefit.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

What is CJC-1295?

CJC-1295 is an experimental long-acting analogue of growth hormone-releasing hormone, a natural signal that prompts the pituitary gland to release growth hormone.

Is CJC-1295 the same as growth hormone?

No. CJC-1295 is designed to extend signalling through the GHRH pathway. It does not replace growth hormone directly.

What did human studies of CJC-1295 find?

Small studies in healthy adults found sustained increases in growth hormone and IGF-1. They did not establish a clinical benefit or long-term safety.

Is a hormone increase proof that CJC-1295 works for recovery?

No. A laboratory change shows pathway activity, not improved recovery. A recovery claim would require controlled trials measuring relevant patient outcomes.

Sources

  1. [1]Teichman et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. Journal of Clinical Endocrinology and Metabolism. 2006. PMID 16352683.Tier 1 · primary↩
  2. [2]Ionescu and Frohman. Pulsatile GH secretion persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology and Metabolism. 2006. PMID 17018654.Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars